Started in Oxford

Since 1997, Isis Innovation has been responsible for creating spin-out companies based on academic research generated within and owned by the University of Oxford, and has spun-out a new company every two months on average.

Over £266 million in external investment has been raised by Isis spin-out companies since 2000, and five are currently listed on London’s AIM market.

The creation of these new spin-out companies also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.

Please note that this page currently shows spinouts from 2012 and later only.

2015

Using phase change materials for smart glazing and displays.

Incorporated in November 2015

Origin: Oxford University, Department of Materials

The OxEML system uses electromagnetic and acoustic waves to create a new class of medical images at a cost comparable to ultrasound.

Incorporated in October 2015

Origin: Oxford University, Department of Engineering

Developing a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine.

Incorporated in July 2015

Origin: Oxford University, Radcliffe Department of Medicine

Developing domestic energy storage capacity and facilitating its operation within the existing power distribution infrastructure.

Incorporated in April 2015

Origin: Oxford University, Department of Engineering

AnDy marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from our environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering.

Incorporated in April 2015

Origin: Oxford University, Department of Zoology

Domain-centric intelligent automated data extraction methodology.

Incorporated in February 2015

Origin: Oxford University, Department of Computer Science

2014

At OxSyBio, we are developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical research and clinical applications. Our vision is to ultimately produce tissues that can be used in the clinic for organ repair or replacement. Professor Bayley’s group have previously demonstrated the ability to print three-dimensional networks comprising tens of thousands of picoliter aqueous droplets forming a cohesive material. These networks can be built in software-controlled geometries using a number of different droplet types, thus enabling them to perform simple cell-like functions and act as ‘tissue-like’ materials. Initial work showed that printed networks were capable of conducting electrical signals along neuron-like pathways by the selective incorporation of membrane proteins, or to fold in a pre-defined manner to assume altered shapes after printing. OxSyBio is refining and advancing this technology to print more complex networks more rapidly and at a higher resolution. We are also adapting the approach to print living cells inside droplets, which will enable the direct printing of 3D cell networks with many of the characteristics of living tissues.

Incorporated in April 2014

Origin: Oxford University, Department of Chemistry

Develop cutting edge software applications that uncover the relationships between genetic variation and human disease. Help pharmaceutical companies de-risk the drug development process.

Incorporated in March 2014

Origin: Oxford University, Wellcome Trust Centre for Human Genetics

A team of security and communication experts creating military-grade authentication security products for business teams.

Incorporated in January 2014

Origin: Oxford University, Department of Computer Science

2013

Developing solutions for major unmet needs in diagnostic medicine in multiple internal organs. In the first instance the focus will be on, the detection and the accurate, quantitative measurement of liver, gallbladder and pancreatic disease, including precancerous and cancerous states in these organs.

Incorporated in April 2013

Origin: Oxford University, Department of Cardiovascular Medicine

2012

© Isis Innovation